AF
FHTX icon

Amalgamated Financial’s Foghorn Therapeutics FHTX Stock Holding History

Amalgamated Financial’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$38K Buy
+2,501
New +$34.3K ﹤0.01% 2535

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Amalgamated Financial's FHTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Foghorn Therapeutics (FHTX) in Q1 2022: 2,501 shares worth $38K. The stake represents ﹤0.01% of the portfolio and ranks #2535 among its holdings.

61 funds tracked by Wall St. Rank hold FHTX as of Q1 2022.

  • Amalgamated Financial held 2,501 shares of Foghorn Therapeutics worth $38K as of Q1 2022.
  • Foghorn Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Foghorn Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2535 holding.
  • 61 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.